Ionis Pharmaceuticals: Goldman Sachs cuts target price to $41 from $58
IONS•Goldman Sachs cut its target price for Ionis Pharmaceuticals to $41 from $58.
Related News
Cullinan Therapeutics Q3 net loss narrows to $49.4 million
CGEM•
Gold drops 1% on hawkish Fed comments ahead of US inflation data
GLD•
Marathon Digital Holdings: Rosenblatt Securities cuts target price to $11 from $15
MARA•
WhiteFiber Q3 revenue rises 19% as NC-1 data center becomes fully operational in late September
WYFI•
BioNTech to buy FDA priority review voucher from Scholar Rock for $205 million
BNTX•